Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00056173 · ClinicalTrials.gov registry record · Phase 1
Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma
A Phase 1 study, sponsored by Aptose Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
NCT00056173: Completed Phase 1 study, sponsored by Aptose Biosciences.
NCT00056173 is a Phase 1 study that has completed, run by Aptose Biosciences. The registered enrollment target is 43 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (28% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00056173, a Phase 1 study, has completed, sponsored by Aptose Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
This phase II, 43 patient trial, will evaluate the efficacy of GTI-2040, an antisense oligonucleotide complementary to the R2 component of ribonucleotide reductase (RNR) mRNA, in combination with capecitabine, in the setting of advanced/metastatic renal cell carcinoma. Preclinical studies have shown synergy between GTI-2040 and capecitabine against renal cell carcinoma.
Interventions
- DRUG GTI-2040
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2002-03 |
| Phase | Phase 1 |
What the finished NCT00056173 record still lists
NCT00056173 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (28% lower).
The record links to 0 conditions, and to 1 intervention - of which GTI-2040 is the first listed.
NCT00056173 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00056173 about?
NCT00056173 is a clinical study titled "Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma". This phase II, 43 patient trial, will evaluate the efficacy of GTI-2040, an antisense oligonucleotide complementary to the R2 component of ribonucleotide reductase (RNR) mRNA, in combination with capecitabine, in the setting of advanced/metastatic renal cell carcinoma. Preclinical studies have shown...
What is the current status of trial NCT00056173?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2002-03.
What interventions are being tested in trial NCT00056173?
The interventions under investigation include: GTI-2040 (DRUG).
Who is sponsoring clinical trial NCT00056173?
This trial is sponsored by Aptose Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00056173's enrollment target sits among peer trials
43 1100th of 2000 higher than 896 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia